Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $24.0 million.

  • Adma Biologics' Accounts Payables rose 4994.38% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 4994.38%. This contributed to the annual value of $20.2 million for FY2024, which is 2911.24% up from last year.
  • As of Q3 2025, Adma Biologics' Accounts Payables stood at $24.0 million, which was up 4994.38% from $29.8 million recorded in Q2 2025.
  • Adma Biologics' Accounts Payables' 5-year high stood at $29.8 million during Q2 2025, with a 5-year trough of $6.2 million in Q2 2021.
  • Over the past 5 years, Adma Biologics' median Accounts Payables value was $14.2 million (recorded in 2024), while the average stood at $16.1 million.
  • In the last 5 years, Adma Biologics' Accounts Payables skyrocketed by 11658.31% in 2021 and then tumbled by 5693.5% in 2023.
  • Over the past 5 years, Adma Biologics' Accounts Payables (Quarter) stood at $12.4 million in 2021, then grew by 6.43% to $13.2 million in 2022, then rose by 18.38% to $15.7 million in 2023, then rose by 29.11% to $20.2 million in 2024, then grew by 18.8% to $24.0 million in 2025.
  • Its Accounts Payables was $24.0 million in Q3 2025, compared to $29.8 million in Q2 2025 and $20.6 million in Q1 2025.